Skip to main content
You are the owner of this article.
You have permission to edit this article.
Edit
UW-Madison facility starts manufacturing COVID-19 treatment drug
topical top story
WAISMAN CENTER | COVID-19 TREATMENT

UW-Madison facility starts manufacturing COVID-19 treatment drug

{{featured_button_text}}
Production bioreactor

Waisman Biomanufacturing staff member Rachel Mosher adjusts the controls on a production bioreactor like the one in which antibodies for a drug developed to treat COVID-19 will be produced.

A lab at UW-Madison’s Waisman Center started manufacturing a new drug to treat COVID-19 patients, the university announced Wednesday.

Waisman Biomanufacturing is working with GigaGen, a California-based biotechnology company, on a drug that uses an approach similar to treating COVID-19 patients with convalescent plasma, or blood products from people recovering from an infection.

The drug, called GIGA-2050, is “one of the most exciting manufacturing challenges we have encountered,” Waisman Biomanufacturing director Carl Ross said in a university announcement.

Chromatography 1

Waisman Biomanufacturing staff member Dave Richards purifies antibodies for a drug developed to treat and prevent COVID-19 developed by the biotech company GigaGen.

GigaGen screened blood donated by people recovering from COVID-19 and found large variation in the amount of antibodies among patients. Antibodies are proteins created by the immune system to detect and fight off a virus.

Manufacturing of the drug relies upon a technique that involves genetically engineering cells to produce many thousands of different antibodies that bind to the virus.

Waisman scientists will analyze and purify the results to manufacture into a drug product for GigaGen. The company creates a variety of antibody drugs for infectious diseases and cancers.

GigaGen reports that lab tests show GIGA-2050 has been more protective against the virus than plasma. The company is planning multiple phases of testing, which will be produced by Waisman Biomanufacturing and a biotech company in Florida.

The Waisman Biomanufacturing center was created to facilitate development of new therapeutic drugs.

Concerned about COVID-19?

* I understand and agree that registration on or use of this site constitutes agreement to its user agreement and privacy policy.

Related to this story

Get up-to-the-minute news sent straight to your device.

Topics

News Alerts

Badger Sports

Breaking News

Crime

Politics